AZNAcerta Pharma BVRunning, no new patients
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 533 (final count)
- Started
- Jul 28, 2015
- Main results expected
- Sep 15, 2020
- Fully finished
- Jan 3, 2028
- Results posted
- Jan 28, 2022
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment
Measured over: Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02477696 · record last updated 2026-08-26 · checked 2026-11-09 15:47 UTC